ARS Pharmaceuticals Q3 net loss $14.9M; neffy NDA resubmission anticipated H1 2024

ARS Pharmaceuticals, Inc.

2023-Q3 EPS reported -$0.50 revenue$30,000

Cash, equivalents and short-term investments $241.9M as of Sep 30, 2023; operating runway ≥3 years.
Net loss $14.9M for Q3 2023; R&D $3.0M, G&A $15.0M.
FDA issued Complete Response Letter in Sep 2023 for neffy; repeat-dose study topline expected Q1 2024.
NDA resubmission planned H1 2024; potential U.S. launch in H2 2024 if approved.
European MAA decision expected Q2 2024; positive clinical results published in JACI.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ARS Pharmaceuticals, Inc. reported three and nine months ended September 30, 2023 results: net income Net loss was $14.9 million for the quarter ended September 30, 2023..

Period: three and nine months ended September 30, 2023
Net income: Net loss was $14.9 million for the quarter ended September 30, 2023.
Result: reported results

Exact text from the filing

ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and nine months ended September 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061989

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.